TITLE

A survey of palivizumab for infants with cystic fibrosis in the UK

AUTHOR(S)
McCormick, J.; Southern, K. W.
PUB. DATE
January 2007
SOURCE
Archives of Disease in Childhood;Jan2007, Vol. 92 Issue 1, p87
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to the article "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants," by the IMpact RSV Study Group that appeared in a previous issue of this periodical.
ACCESSION #
23779070

 

Related Articles

  • Bronchiolitis: First do no harm. McMillan, Julia A. // Contemporary Pediatrics;Feb2008, Vol. 25 Issue 2, p13 

    An introduction to articles published within the issue is presented, including an article on the recommended treatment for respiratory syncytial virus (RSV) and bronchiolitis.

  • Antibody against RSV helps prevent wheeze in infants.  // BMJ: British Medical Journal;5/18/2013, Vol. 346 Issue 7908, p11 

    The article reports that Palivizumab, a monoclonal antibody, directed against respiratory syncytial virus (RSV) helps in preventing wheeze or asthma in infants.

  • Virus imaged. Coledan, Stefano; Dunn, Brad; Gourley, Scott; Schrader, Richard // Popular Mechanics;Jun98, Vol. 175 Issue 6, p18 

    Reports that crystals grown on the Columbia space shuttle mission may help cure respiratory syncytial virus. Significance of the determination of a potential antibody's structure through the crystals.

  • RSV F-Protein Vaccine Clinical Trial Yields Positive Top-Line Results.  // Journal of Gerontological Nursing;2015, Vol. 41 Issue 11, p6 

    The article discusses the results obtained by Novavax Inc. for its respiratory syncytial virus (RSV) F-protein recombinant nanoparticle vaccine. Topics included are the safety and immunogenicity indicated by top-line data from their Phase 2 clinical trial, the statistical validation of vaccine...

  • Synagis Trademark: An Anti-RSV Monoclonal Antibody. Farrington, Elizabeth; Driver, Leslie C.; Oertel, Maryann D. // Pediatric Nursing;Sep/Oct99, Vol. 25 Issue 5, p527 

    Provides information on Palivizumab, a treatment for respiratory syncytial virus (RSV) which causes pneumonia and bronchitis in early infancy and childhood. Details of RSV infection; Background of Palivizumab; Clinical efficacy; Adverse effects; Dosage; Preparation and administration;...

  • Viral attack. Moore, Eilish // World of Irish Nursing & Midwifery;Mar2015, Vol. 23 Issue 2, p44 

    No abstract available.

  • A Network Flow Approach to Predict Protein Targets and Flavonoid Backbones to Treat Respiratory Syncytial Virus Infection. Vargas, José Eduardo; Puga, Renato; Poloni, Joice de Faria; Saraiva Macedo Timmers, Luis Fernando; Porto, Barbara Nery; Norberto de Souza, Osmar; Bonatto, Diego; Condessa Pitrez, Paulo Márcio; Tetelbom Stein, Renato // BioMed Research International;3/23/2015, Vol. 2015, p1 

    Background. Respiratory syncytial virus (RSV) infection is the major cause of respiratory disease in lower respiratory tract in infants and young children. Attempts to develop effective vaccines or pharmacological treatments to inhibit RSV infection without undesired effects on human health have...

  • A Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Efficacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus. Schuster, Jennifer E.; Cox, Reagan G.; Hastings, Andrew K.; Boyd, Kelli L.; Wadia, Jay; Chen, Zhifeng; Burton, Dennis R.; Williamson, R. Anthony; Williams, John V. // Journal of Infectious Diseases;Jan2015, Vol. 211 Issue 2, p216 

    Background Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infection, with significant morbidity and mortality. No licensed vaccines or therapeutic agents exist. Monoclonal antibodies (mAbs) are effective at preventing other infectious diseases and could be used...

  • DISCUSSION.  // Infectious Diseases in Children;Mar2011 Supplement, p14 

    The article presents questions and answers related to the treatment of respiratory syncytial virus (RSV) including the use of hypertonic saline as a treatment option for RSV, apnea in RSV and the reasons why the American Academy of Pediatrics reduced the recommended number of doses of palivizumab.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics